Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $33.00.
Several brokerages recently weighed in on RNA. Roth Capital started coverage on Avidity Biosciences in a research report on Thursday, October 22nd. They issued a “buy” rating and a $15.00 price objective for the company. Weiss Ratings upgraded Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. Finally, HC Wainwright decreased their price target on Avidity Biosciences from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, October 28th.
Check Out Our Latest Stock Analysis on RNA
Avidity Biosciences Stock Up 0.1%
NASDAQ:RNA traded up $0.01 on Friday, hitting $7.51. The stock had a trading volume of 195,172 shares, compared to its average volume of 224,456. The company has a fifty day moving average price of $8.65 and a two-hundred day moving average price of $18.25. Avidity Biosciences has a 1-year low of $7.47 and a 1-year high of $16.77. The stock has a market cap of $128.50 million and a price-to-earnings ratio of -3.49.
Avidity Biosciences (NASDAQ:RNA – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.56. The firm had revenue of $15.32 million for the quarter, compared to analyst estimates of $15.00 million. As a group, analysts anticipate that Avidity Biosciences will post -4.45 earnings per share for the current year.
Institutional Trading of Avidity Biosciences
A hedge fund recently bought a new stake in Avidity Biosciences stock. Hsbc Holdings PLC purchased a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,729 shares of the biotechnology company’s stock, valued at approximately $2,360,000.
About Avidity Biosciences
Avidity Biosciences is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells. The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.
Further Reading
- Five stocks we like better than Avidity Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
